Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia

Human Psychopharmacology

Volumn 24, Issue 8, 2009, Pages 639-645

  Goto, Naoki ^a   Yoshimura, Reiji ^a   Kakeda, Shingo ^a   Moriya, Junji ^a   Hayashi, Kenji ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Hori, Hikaru ^a   Ueda, Nobuhisa ^a   Korogi, Yukunori ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; HOMOVANILLIC ACID;

ADOLESCENT; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; HUMAN; MALE; NORADRENERGIC NERVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; WORKING MEMORY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; FEMALE; FRONTAL LOBE; GAMMA-AMINOBUTYRIC ACID; HOMOVANILLIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NEURONS; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 73449105054     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1070     Document Type: Article

References (49)

1. Berridge C, Waterhouse B. 2003. The locus coeruleus-noradrenergic systems: modulation of behavioral state and state-dependent cognitive process. Brain Res Brain Rev 42: 33-84.
2. Braff DL, Geyer MA. 1990. Sensorimotor gaiting and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47: 181-190.
3. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. 2007. Brain derived neurotrophic factor in first-episode psychosis. Schizophr Res 91: 1-5.
4. Daniel DG, Weinberger DR, Jones DW, et al. 1991. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11: 1907-1917.
5. Eckhoff P, Wong-Lin KF, Holmes P. 2009. Optimality and robustness of a biophysical decision-making model under norepinephrine modulation. J Neurosci 29: 4301-4311.
6. First MB, Spitzer RL, Gibbon M, Williams JBW. 1995. Structured clinical interview for DSM-IVaxis I disorders, Patient edition (SCID-P), version 2 New York State Psychiatric Institute, Biometrics Research, New York.
7. Friis S, Sundet K, Rund BR, Vaglum P, McGlashan TH. 2002. Neurocognitive dimensions characterizing patients with first-episode psychosis. Br J Psychiatry 181(suppl 43): 85-90.
8. Goldberg TE,Weinberger DR. 1990. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull 14: 179-184.
9. Goto N, Yoshimura R, Ueda N, et al. 2009. Reduction of brain γ-aminobutylic acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res 112: 192-193.
10. Goto N, Yoshimura R, Kakeda S, et al. Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with early-stage schizophrenia and healthy controls. Eur Psychiatry, in press.
11. Grillo RW, Ottoni G, Leke R, Souza DO, Portela LV, Lara DR. 2007. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41: 31-35.
12. Hoff AL, Kremen WS. 2002. Is there a cognitive phenotype for schizophrenia: the nature and course of the disturbance in cognition? Curr Opin Psychiatry 15: 43-48.
13. Hori H, Yoshimura R, Yamada Y, et al. 2007. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 22: 21-27.
14. Kahn RS, Harvey PD, Davidson M, et al. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res 11: 217-224.
15. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
16. Kopin IJ. 1985. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37: 333-364.
17. Lanser MG, Berger HJC, Ellenbroek BA, Cools AR, Zitman FG. 2002. Perseveration in schizophrenia: failure to generate a plan and relationship with the psychomotor poverty subsyndrome. Psychiat Res 112: 13-26.
18. Lauder JM, Han VK, Henderson P, Verdoorn T, Towle AC. 1986. Prenatal ontogeny of the GABAergic system in the rat brain: an immunocytochemical study. Nuroscience 19: 465-493.
19. Lei S, Deng PY, Porer JE, Shin HS. 2007. Adrenergic facilitation of GABAergic transmission in rat entorhinal cortex. J Neurophysiol 98: 2868-2877.
20. Lewis DA, Hashimoto T, Volk DW. 2005. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324.
21. Liu Z, Zhao J, Tan WC. 2003. Attention and executive function impairments in unaffected siblings of patients with schizophrenia. Hong Kong J Psychiatry 13: 8-11.
22. Mescher M, Merkle H, Kirsh J, Garwood M, Gruetter M. 1998. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 11: 266-272.
23. Minegishi A, Ishizaki T. 1984. Determination of free 3-methoxy-4- hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatgr 311: 51-57.
24. Nagaoka S, Iwamoto N, Arai H. 1997. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to haloperidol treatment. Biol Psychiatry 41: 857-864.
25. Nai Q, Dong HW, Hayar A, Linster C, Ennis M. 2009. Noradrenergic regulation of GABAergic inhibition of main olfactory bulb mitral cells varies as a function of concentration and receptor subtype. J Neurophysiol 101: 2472-2484.
26. Nieuwenstein MR, Aleman A, De Haan EHF. 2001. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a metaanalysis of WCST and CPT studies. J Psychiatr Res 35: 119-125.
27. Pendleton MG, Heaton RK. 1982. A comparison of the Wisconsin Card Sorting Test and the Category Test. J Clin Psychol 38: 392-396.
28. Pietrzak RH, Snyder PJ, Jackson CE, et al. 2009. Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals. Hum Psychopharmacol 24: 113-121.
29. Pirildar S, Gonul AS, Taneli F, Akdeniz F. 2004. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog-Neuropsychopharmacol Biol Psychiatry 28: 709-713.
30. Provenhcar SW. 1993. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnet Resonance Med 30: 672-679.
31. Radley JJ,Williams B, Sawchenko PE. 2008. Noradrenergic intervention of the dorsal medial prefrontal cortex modulates hypothalamo-pituitary-adrenal response to acute emotional stress. J Neirosci 28: 5806-5816.
32. Rao SG, Williams GV, Goldman-Rakic PS. 2000. Destruction and creation of spatial tuning by disinhibition: GABAA. blockade of prefrontal cortical neurons engaged by working memory. J. Neurosci. 20: 485-494.
33. Ren ZG, Porzgen PP, Youn YH, Sieber-Blum M. 2003. Ubiquitous embryonic expression of the norepinephrine transporter. Dev Neurosci 25: 1-13.
34. Sawaguchi T, Matsumura M, Kubota K. 1988. Delayed response deficit in monkeys by locally disturbed prefrontal neuro activity by bicuculline. Behav Brain Res 31: 193-198.
35. Saykin A, Gur RC, Gur RE, et al. 1991. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48: 618-624.
36. Shimizu E, Hashimoto K, Watanabe H, et al. 2003. Serum brain-drived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351: 111-114.
37. Tan YL, Zhou DF, Cao LY, Zhang XY. 2005. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382: 27-32.
38. Toyooka K, Asama K, Watanabe Y, et al. 2002. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110: 249-257.
39. Umene-Nakano W, Yoshimura R, Ikenouchi-Sugita A, et al. 2009. Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence. Hum Psychopharmacol 24: 409-413.
40. Vinogradov S, Fisher M, Holland C, Sherry W, Wolkowitz O, Mellon SH. 2009. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 66: 549-553.
41. Weicker H. 1986. Sympathoadrenergic regulation. Int J Sports Med 7 Suppl 1: 16-26.
42. Weinberger DR, Berman KF, Illowsky BP. 1988. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence. Arch Gen Psychiatry 45: 609-615.
43. Yeung PKF, Buckley SJ, Pedder SCJ, Dingemanse J. 1996. Determination of 3,4-dihydroxyphenylphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 85: 451-453.
44. Yoshimura R, Hori H, Sugita A, et al. 2007. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31: 1072-1077.
45. Yoshimura R, Nakamura J, Ueda N, Terao T. 2000b. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels and clinical improvement. Int Clin Psychopharmacol 15: 175-180.
46. Yoshimura R, Shinkai K, Toyohira Y, Ueno S, Yanagihara N, Nakamura J. 2005. Effects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells. Hum Psychopharmacol 20: 477-484.
47. Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. 2008. Differential patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-drived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2: 1-6 [Epub ahead of print].
48. Yoshimura R, Yanagihara N, Hara K, et al. 2000a. I nhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells. Psychopharmacology. 149: 17-23.
49. Yoshimura R, Yanagihara N, Hara K, et al. 2001. Dual phase of functional change in norepinephrine transporter in cultured bovine adrenal medullary cells by long-term treatment with clozapine. J Neurochem 77: 1018-1026.